Cerevel Therapeutics Holdings, Inc.
CERE
Classificação em ações
#2810
Cerevel Therapeutics Holdings, Inc. is a clinical-stage biopharmaceutical firm... Cerevel Therapeutics Holdings, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing treatments for a range of neuroscience disorders. The company boasts a robust pipeline of therapeutic candidates currently undergoing various phases of clinical evaluation. Key assets include emraclidine, a positive allosteric modulator (PAM) in Phase 1b trials for schizophrenia. Another PAM, Darigabat, is being assessed in a Phase 2 proof-of-concept study for drug-resistant focal onset seizures in epilepsy, as well as in a Phase 1 trial for acute anxiety. For Parkinson's disease, Cerevel is advancing Tavapadon, a selective dopamine D1/D5 partial agonist, through Phase 3 clinical trials for both early and late stages of the condition. A related compound, CVL-871, also a selective dopamine D1/D5 partial agonist, is in Phase 2a trials for dementia-related apathy. The company's portfolio further includes CVL-936, a selective dopamine D3-preferring antagonist in Phase I for substance use disorder; CVL-354, a selective kappa-opioid receptor antagonist targeting major depressive disorder and substance use disorder; and CVL-047, a selective PDE4 inhibitor also aimed at major depressive disorder and substance use disorder. Beyond individual compounds, Cerevel is actively developing an M4 agonist program for psychosis and related indications, alongside an LRRK2 inhibitor program designed to address the progression of Parkinson's disease. Founded in 2018, Cerevel Therapeutics is headquartered in Cambridge, Massachusetts.
Preço da ação
$44.96
Última sincronização: 2024-08-01
Valor de mercado
$6.67B
Variação (1 dia)
0.00%
Variação (1 ano)
0.00%
País
US
Negociar Cerevel Therapeutics Holdings, Inc. (CERE)
Categoria
Healthcare
Rácio P/B de Cerevel Therapeutics Holdings, Inc. (CERE)
Rácio P/B em October 2026 TTM: 10.81
De acordo com os relatórios financeiros mais recentes e o preço das ações da Cerevel Therapeutics Holdings, Inc., o rácio P/B atual (TTM) é 10.81. No final de 2022, o rácio P/B era 9.15.
Histórico do rácio P/B da Cerevel Therapeutics Holdings, Inc. de 2012 a 2026
Rácio P/B no final de cada ano
| Ano | Rácio P/B | Alterar |
|---|---|---|
| 2026 (TTM) | 10.81 | 6.02% |
| 2023 | 10.20 | 11.42% |
| 2022 | 9.15 | 19.63% |
| 2021 | 7.65 | 50.14% |
| 2020 | 5.10 | -73.79% |
| 2019 | 19.44 | 0.00% |
| 2018 | 0.00 | -100.00% |
| 2015 | 40.22 | 555.33% |
| 2014 | 6.14 | 19.55% |
| 2013 | 5.13 | 89.54% |
| 2012 | 2.71 | 0.00% |
Rácio P/B de empresas semelhantes ou concorrentes
| Empresa | Rácio P/B | Diferença do rácio P/B | País |
|---|---|---|---|
| 6.251 | -42.20% |
US
|
|
| 13.2547 | 22.57% |
US
|
|
| 4.208 | -61.09% |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | -42.83% |
NL
|
